Frequency of XXXX and @entity18246 expression in bladder cancer and evidence of a new @entity16051 T-cell epitope in a @entity1 with bladder cancer.

@entity1 @entity2558 @entity1803 @entity5 @entity1606 @entity16051 @entity18246
@entity5 ( @entity5 ) antigens are ideal vaccine targets since their expression is restricted in adult tissues to testicular germ cells and a subset of @entity5 . The frequency of @entity1606 (TCCs) of @entity16051 , the most immunogenic @entity5 antigen to date, and its closely related gene @entity18246 was studied. @entity16051 and @entity18246 antigen expression were found to occur frequently in high-grade TCC @entity5 . On an MSKCC IRB-approved protocol, 68 @entity1 specimens were collected prospectively at the time of transurethral resection or cystectomy, of which 43 were read pathologically as high-grade @entity5 (pCIS, pTaG3, @entity2558 , pT2, @entity1803 , and pT4), 8 as @entity5 (pTaG1, pTaG2), and 17 as disease-free samples. These 68 samples were analyzed by immunohistochemistry (IHC) and/or RT-PCR. There were also an additional 53 paraffin-embedded specimens studied retrospectively by IHC, of which 39 were high-grade @entity5 and 14 were @entity5 . Cumulatively, our data indicate that @entity16051 and/or @entity18246 are expressed in 39/82 (48%) high-grade TCC and 3/22 (14%) low-grade TCC samples when analyzed by RT-PCR and/or IHC. Immunological assessment of these @entity1 ' sera identified one @entity1 , whose @entity5 homogeneously expressed @entity16051 , which had detectable antibodies against @entity16051 and @entity18246 . Further analysis of this @entity1 , who remains clinically without evidence of disease 24 months after cystectomy for high-grade pT4 disease, revealed T-cell immunity against @entity16051 . This @entity1 's T-cell response was determined to be specific for a new @entity16051 epitope, p94-102, in the context of HLA-B35.
